New In Vitro 3D Functional Model of Tumorigenesis

描述(申请人提供)：在我们最初的研发工作中，我们成功地证明了一种新型的人类生物基质系统(HuBiogel)在设计3D生物测试系统用于肿瘤形成过程体外检测的可行性。总体目标过去和现在都是开发和商业化这些人体生物检测系统。第一阶段的工作明确表明，新的检测模型比传统的单层细胞培养和动物来源的生物基质系统显示出许多优势。为了实时分析肿瘤生长和血管生成，建立了确定生物活性或环境的HuBiogel分析。基于该项目的临床相关性，我们还启动了与两位著名癌症研究人员的积极合作。有了这项前景看好的技术，我们提出了三项扩展任务，以全面实现我们的研发目标。它们是：1)利用自动化技术建立高效的BioMatrix生产、分析和配方方案；2)使用人乳腺和脑肿瘤细胞模型完成3D肿瘤生长、侵袭和血管生成分析平台的开发；3)通过成熟的细胞和分子分析技术验证HuBiogel分析的功能特性。我们的集成技术将允许对肿瘤发生级联进行精确的实时分析。新的3D分析技术将提供更多的临床意义，因为它模拟了人类肿瘤的生物学和功能。这一先进的生物测定系统将用于肿瘤发生早期和晚期的终点分析、特定正负调节因子的平行评估以及肿瘤细胞或活组织的表型分析。因此，这一前景看好的研发项目的及时完成将对癌症生物学、药物发现和治疗研究市场产生积极影响。项目相关性：目前还没有可接受的使用自然或定义的人类生物矩阵系统的商业肿瘤分析模型。VBI将开发可重复使用和一次性的3D肿瘤生长、侵袭和血管生成测试平台。HuBiogel、预包装化验试剂盒和内部药物测试服务的销售将在基础、生物医学和癌症研究领域拥有重要的全球市场。

DESCRIPTION (provided by applicant): In our initial R&D effort we successfully demonstrated the feasibility of a novel human biomatrix system (HuBiogel) in designing 3D bioassay system for in vitro examination of tumorigenesis process. The overall goal was and is to develop and commercialize these human bioassay systems. Phase I work definitely established that new assay models exhibit many advantages over conventional monolayer cell cultures and animal-derived biomatrix systems. HuBiogel assays of defined bioactivity or environment are established for real-time analysis of tumor growth and angiogenesis. Based on project's clinical relevance, we also initiated active collaborations with two renowned cancer researchers. With this promising technology, we propose three extended tasks to fully accomplish our R&D goals. They are: 1) Establish efficient protocols for biomatrix production, analysis and formulation at commercial scale using automated technologies; 2) Complete the development of 3D tumor growth, invasion and angiogenesis assay platform using human breast and brain tumor cell models; 3) Validate functional properties of HuBiogel assays by established cellular and molecular analysis techniques. Our integrated technology will allow precise real-time analysis of tumorigenesis cascade. New 3D assay technology will provide more clinical relevance as it emulates human tumor-like biology and function. This advanced bioassay system will be useful for endpoint analysis of early to late tumorigenesis stages, parallel evaluation of specific positive and negative regulators and phenotypic profiling of tumor cells or biopsies. Thus, the timely completion of this promising R&D project will positively impact cancer biology, drug discovery and therapeutic research markets. Project Relevance: No acceptable commercial tumor assay model currently exists which utilizes a natural or defined human biomatrix system. VBI will develop reusable and disposable 3D tumor growth, invasion and angiogenesis assay platforms. Sale of HuBiogel, pre-packed assay kits and in-house drug testing services would have a significant world-wide market in basic, biomedical and cancer research fields.